OXBRYTA Drug Patent Profile
✉ Email this page to a colleague
When do Oxbryta patents expire, and what generic alternatives are available?
Oxbryta is a drug marketed by Global Blood Theraps and is included in two NDAs. There are eleven patents protecting this drug and two Paragraph IV challenges.
This drug has two hundred and seventy-six patent family members in forty countries.
The generic ingredient in OXBRYTA is voxelotor. One supplier is listed for this compound. Additional details are available on the voxelotor profile page.
DrugPatentWatch® Generic Entry Outlook for Oxbryta
Oxbryta was eligible for patent challenges on November 25, 2023.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 6, 2035. This may change due to patent challenges or generic licensing.
There are two Paragraph IV patent challenges for this drug. This may lead to patent invalidation or a license for generic production.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OXBRYTA?
- What are the global sales for OXBRYTA?
- What is Average Wholesale Price for OXBRYTA?
Summary for OXBRYTA
| International Patents: | 276 |
| US Patents: | 11 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 48 |
| Clinical Trials: | 5 |
| Patent Applications: | 98 |
| Drug Prices: | Drug price information for OXBRYTA |
| What excipients (inactive ingredients) are in OXBRYTA? | OXBRYTA excipients list |
| DailyMed Link: | OXBRYTA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for OXBRYTA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for OXBRYTA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pfizer | Phase 1 |
| Global Blood Therapeutics | Phase 2 |
| Emory University | Phase 2 |
Pharmacology for OXBRYTA
| Drug Class | Hemoglobin S Polymerization Inhibitor |
| Mechanism of Action | Cytochrome P450 3A4 Inhibitors Hemoglobin S Polymerization Inhibitors |
US Patents and Regulatory Information for OXBRYTA
OXBRYTA is protected by thirteen US patents and three FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of OXBRYTA is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting OXBRYTA
Compounds and uses thereof for the modulation of hemoglobin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzald- ehyde
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzald- ehyde
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzald- ehyde
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY
Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzald- ehyde
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: INCREASING HEMOGLOBIN TO TREAT SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR AND ANOTHER ACTIVE AGENT
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 10
Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
1:1 adducts of sickle hemoglobin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 1
1:1 adducts of sickle hemoglobin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 2
Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzald- ehyde
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting OXBRYTA
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
FOR TREATMENT OF SICKLE CELL DISEASE (SCD) IN PEDIATRIC PATIENTS 4 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE
Exclusivity Expiration: ⤷ Sign Up
INDICATED FOR THE TREATMENT OF SICKLE CELL DISEASE (SCD) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-001 | Nov 25, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-001 | Nov 25, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-001 | Nov 25, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-002 | Oct 14, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-002 | Oct 14, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET, FOR SUSPENSION;ORAL | 216157-001 | Dec 17, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-002 | Oct 14, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for OXBRYTA
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Pfizer Europe MA EEIG | Oxbryta | Voxelotor | EMEA/H/C/004869 Oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide. |
Authorised | no | no | yes | 2022-02-14 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for OXBRYTA
When does loss-of-exclusivity occur for OXBRYTA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 9304
Patent: POLIMORFOS CRISTALINOS DE LA BASE LIBRE DEL 2-HIDROXI-6-((2-(1-ISOPROPIL-1H-PIRAZOL-5-IL)PIRIDIN-3-IL)METOXI)BENZALDEHÍDO
Estimated Expiration: ⤷ Sign Up
Patent: 0638
Patent: COMPRIMIDOS QUE COMPRENDEN 2-HIDROXI-6-((2-(1-ISOPROPIL-1H-PIRAZOL-5-IL)PIRIDIN-3-IL)METOXI)BENZALDEHÍDO
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 15214182
Patent: Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Estimated Expiration: ⤷ Sign Up
Patent: 20207778
Patent: CRYSTALLINE POLYMORPHS OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
Estimated Expiration: ⤷ Sign Up
Patent: 22203213
Patent: CRYSTALLINE POLYMORPHS OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2015032160
Patent: polimorfos cristalinos da base livre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldeído
Estimated Expiration: ⤷ Sign Up
Patent: 2019006506
Patent: comprimidos compreendendo 2-hi¬dróxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metóxi) benzaldeído
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 16564
Patent: POLYMORPHES CRISTALLINS DE LA BASE LIBRE DE 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE (CRYSTALLINE POLYMORPHS OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE)
Estimated Expiration: ⤷ Sign Up
China
Patent: 5431147
Patent: Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Estimated Expiration: ⤷ Sign Up
Patent: 4181194
Patent: 一种化合物的结晶多晶型物 (Crystalline polymorphic substance of compound)
Estimated Expiration: ⤷ Sign Up
Patent: 4181195
Patent: 一种化合物的结晶多晶型物 (Crystalline polymorphic substance of compound)
Estimated Expiration: ⤷ Sign Up
Patent: 4213390
Patent: 一种化合物的结晶多晶型物 (Crystalline polymorphic substance of compound)
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0210388
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 24097
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 02208
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 8529
Patent: КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ СВОБОДНОГО ОСНОВАНИЯ 2-ГИДРОКСИ-6-((2-(1-ИЗОПРОПИЛ-1Н-ПИРАЗОЛ-5-ИЛ)ПИРИДИН-3-ИЛ)МЕТОКСИ)БЕНЗАЛЬДЕГИДА (CRYSTALLINE POLYMORPH FORMS OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE)
Estimated Expiration: ⤷ Sign Up
Patent: 1592212
Patent: КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ СВОБОДНОГО ОСНОВАНИЯ 2-ГИДРОКСИ-6-((2-(1-ИЗОПРОПИЛ-1Н-ПИРАЗОЛ-5-ИЛ)ПИРИДИН-3-ИЛ)МЕТОКСИ)БЕНЗАЛЬДЕГИДА
Estimated Expiration: ⤷ Sign Up
Patent: 1791587
Patent: КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ СВОБОДНОГО ОСНОВАНИЯ 2-ГИДРОКСИ-6-((2-(1-ИЗОПРОПИЛ-1Н-ПИРАЗОЛ-5-ИЛ)ПИРИДИН-3-ИЛ)МЕТОКСИ)БЕНЗАЛЬДЕГИДА
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 02208
Patent: POLYMORPHES CRISTALLINS DE LA BASE LIBRE DE 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)MÉTHOXY)BENZALDÉHYDE (CRYSTALLINE POLYMORPHS OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE)
Estimated Expiration: ⤷ Sign Up
Patent: 25766
Patent: COMPRIMÉS COMPRENANT DE 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)MÉTHOXY)BENZALDÉHYDE (TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE)
Estimated Expiration: ⤷ Sign Up
Patent: 68745
Patent: POLYMORPHES CRISTALLINS DE LA BASE LIBRE DE 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)MÉTHOXY)BENZALDÉHYDE (CRYSTALLINE POLYMORPHS OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 53706
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 3214
Patent: פולימורפים גבישיים של הבסיס החופשי של 2 - הידרוקסי - 6 - ((2 - (1 - איזופרופיל - 1h - פיראזול - 5 - יל) פירידין - 3 - יל) מתוקסי) בנזאלדהיד (Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde)
Estimated Expiration: ⤷ Sign Up
Patent: 5777
Patent: טבליות המכילות 2-הידרוקסי-6-((2-(1-איזופרופיל-h1-פיראזול-5-איל)פירידין-3-איל)מתוקסי)בנזאלדהיד (Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde)
Estimated Expiration: ⤷ Sign Up
Patent: 5918
Patent: פולימורפים גבישיים של הבסיס החופשי של 2-הידרוקסי-6-((2-(1-איזופרופיל-1h-פיראזול-5-יל)פירידין-3-יל)מתוקסי)בנזאלדהיד (Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde)
Estimated Expiration: ⤷ Sign Up
Patent: 6014
Patent: טבליות המכילות 2-הידרוקסי-6-((2-(1-איזופרופיל-1h-פיראזול-5-איל)פירידין-3-איל)מתוקסי)בנזאלדהיד (Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 09681
Estimated Expiration: ⤷ Sign Up
Patent: 17505347
Patent: ２−ヒドロキシ−６−（（２−（１−イソプロピル−１Ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形
Estimated Expiration: ⤷ Sign Up
Patent: 19137699
Patent: ２−ヒドロキシ−６−（（２−（１−イソプロピル−１Ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形 (CRYSTALLINE POLYMORPHS OF FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE)
Estimated Expiration: ⤷ Sign Up
Patent: 21113225
Patent: ２−ヒドロキシ−６−（（２−（１−イソプロピル−１Ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形 (CRYSTALLINE POLYMORPHS OF FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE)
Estimated Expiration: ⤷ Sign Up
Patent: 23016994
Patent: ２－ヒドロキシ－６－（（２－（１－イソプロピル－１Ｈ－ピラゾール－５－イル）ピリジン－３－イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 02208
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 9995
Patent: CRYSTALLINE POLYMORPHS OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 1810
Patent: POLIMORFOS CRISTALINOS DE LA BASE LIBRE DE 2-HIDROXI-6-((2-(1-ISOP ROPIL-1H-PIRAZOL-5-IL-)PIRIDIN-3-IL)METOXI)BENZALDEHIDO. (CRYSTALLINE POLYMORPHS OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISO PROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE.)
Estimated Expiration: ⤷ Sign Up
Patent: 15017614
Patent: POLIMORFOS CRISTALINOS DE LA BASE LIBRE DE 2-HIDROXI-6-((2-(1-ISOP ROPIL-1H-PIRAZOL-5-IL-)PIRIDIN-3-IL)METOXI)BENZALDEHIDO. (CRYSTALLINE POLYMORPHS OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISO PROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE.)
Estimated Expiration: ⤷ Sign Up
Patent: 19004120
Patent: COMPRIMIDOS QUE COMPRENDEN 2-HIDROXI-6-((2-(1-ISOPROPIL-1H-PIRAZOL -5-IL)PIRIDIN-3-IL)METOXI)BENZALDEHIDO. (TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)P YRIDIN-3-YL)METHOXY)BENZALDEHYDE.)
Estimated Expiration: ⤷ Sign Up
Patent: 22007912
Patent: POLIMORFOS CRISTALINOS DE LA BASE LIBRE DE 2-HIDROXI-6-((2-(1-ISOP ROPIL-1H-PIRAZOL-5-IL)PIRIDIN-3- IL)METOXI)BENZALDEHIDO. (CRYSTALLINE POLYMORPHS OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISO PROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE.)
Estimated Expiration: ⤷ Sign Up
Patent: 23004255
Patent: COMPRIMIDOS QUE COMPRENDEN 2-HIDROXI-6-((2-(1-ISOPROPIL-1H-PIRAZOL -5-IL)PIRIDIN-3-IL)METOXI)BENZALDEHIDO. (TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)P YRIDIN-3-YL)METHOXY)BENZALDEHYDE.)
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 522
Patent: COMPRIMÉS COMPRENANT DE 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)MÉTHOXY)BENZALDÉHYDE
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 5029
Patent: Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 160179
Patent: POLIMORFOS CRISTALINOS DE LA BASE LIBRE DE 2-HIDROXI-6-((2-(1-ISOPROPIL-1H-PIRAZOL-5-IL)PIRIDIN-3-IL)METOXI)BENZALDEHIDO
Estimated Expiration: ⤷ Sign Up
Patent: 201444
Patent: POLIMORFOS CRISTALINOS DE LA BASE LIBRE DE 2-HIDROXI-6-((2-(1-ISOPROPIL-1H-PIRAZOL-5-IL)PIRIDIN-3-IL)METOXI)BENZALDEHIDO
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 02208
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 02208
Estimated Expiration: ⤷ Sign Up
Saudi Arabia
Patent: 6370358
Patent: اشكال بلورية متعددة من القاعدة الحرة من 2-هيدروكسي-6-((2-(1-أيزوبروبيل-1H-بيرازول-5-يل) بيريدين-3-يل)ميثوكسي) بنزالديهيد (Crystalline Polymorphs of the Free Base of 2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde)
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 653
Patent: KRISTALNI POLIMORFNI OBLIK SLOBODNE BAZE 2-HIDROKSI-6-((2-(1-IZOPROPIL-1H-PIRAZOL-5-IL)PIRIDIN-3-IL)METOKSI)BENZALDEHID (CRYSTALLINE POLYMORPH OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE)
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 201804139V
Patent: CRYSTALLINE POLYMORPHS OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
Estimated Expiration: ⤷ Sign Up
Patent: 201911662Y
Patent: CRYSTALLINE POLYMORPHS OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
Estimated Expiration: ⤷ Sign Up
Patent: 201911668V
Patent: CRYSTALLINE POLYMORPHS OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
Estimated Expiration: ⤷ Sign Up
Patent: 201510135X
Patent: CRYSTALLINE POLYMORPHS OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 02208
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2345380
Estimated Expiration: ⤷ Sign Up
Patent: 2588476
Estimated Expiration: ⤷ Sign Up
Patent: 160118204
Patent: 2-하이드록시-6-((2-(1-이소프로필-1H-피라졸-5-일)피리딘-3-일)메톡시)벤즈알데하이드의 유리 염기의 결정성 다형체 (2--6-2-1--1H--5--3- CRYSTALLINE POLYMORPHS OF THE FREE BASE OF 2-HYDROXY-6-2-1-ISOPROPYL-1H-PYRAZOL-5-YLPYRIDIN-3-YLMETHOXYBENZALDEHYDE)
Estimated Expiration: ⤷ Sign Up
Patent: 220002722
Patent: 2-하이드록시-6-((2-(1-이소프로필-1H-피라졸-5-일)피리딘-3-일)메톡시)벤즈알데하이드의 유리 염기의 결정성 다형체 (2--6-2-1--1H--5--3- CRYSTALLINE POLYMORPHS OF THE FREE BASE OF 2-HYDROXY-6-2-1-ISOPROPYL-1H-PYRAZOL-5-YLPYRIDIN-3-YLMETHOXYBENZALDEHYDE)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 60648
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 70265
Estimated Expiration: ⤷ Sign Up
Patent: 14182
Estimated Expiration: ⤷ Sign Up
Patent: 55952
Estimated Expiration: ⤷ Sign Up
Patent: 78983
Estimated Expiration: ⤷ Sign Up
Patent: 99115
Estimated Expiration: ⤷ Sign Up
Patent: 1612171
Patent: Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Estimated Expiration: ⤷ Sign Up
Patent: 1815384
Patent: Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Estimated Expiration: ⤷ Sign Up
Patent: 2003489
Patent: Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Estimated Expiration: ⤷ Sign Up
Patent: 2134227
Patent: Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Estimated Expiration: ⤷ Sign Up
Patent: 2245761
Patent: Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Estimated Expiration: ⤷ Sign Up
Patent: 2332423
Patent: Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering OXBRYTA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Singapore | 10201911662Y | CRYSTALLINE POLYMORPHS OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE | ⤷ Sign Up |
| Japan | 6401771 | ⤷ Sign Up | |
| Taiwan | I755952 | ⤷ Sign Up | |
| Argentina | 099304 | POLIMORFOS CRISTALINOS DE LA BASE LIBRE DEL 2-HIDROXI-6-((2-(1-ISOPROPIL-1H-PIRAZOL-5-IL)PIRIDIN-3-IL)METOXI)BENZALDEHÍDO | ⤷ Sign Up |
| Eurasian Patent Organization | 028529 | КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ СВОБОДНОГО ОСНОВАНИЯ 2-ГИДРОКСИ-6-((2-(1-ИЗОПРОПИЛ-1Н-ПИРАЗОЛ-5-ИЛ)ПИРИДИН-3-ИЛ)МЕТОКСИ)БЕНЗАЛЬДЕГИДА (CRYSTALLINE POLYMORPH FORMS OF THE FREE BASE OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE) | ⤷ Sign Up |
| Japan | 6690861 | ⤷ Sign Up | |
| Japan | 2016512824 | ヘモグロビンの修飾のための化合物及びその使用 | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for OXBRYTA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2797416 | 2290032-8 | Sweden | ⤷ Sign Up | PRODUCT NAME: VOXELOTOR OR A TAUTOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/21/1622 20220215 |
| 2797416 | 122022000052 | Germany | ⤷ Sign Up | PRODUCT NAME: VOXELOTOR ODER EIN TAUTOMER ODER PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1622 20220214 |
| 2797416 | 22C1042 | France | ⤷ Sign Up | PRODUCT NAME: VOXELOTOR OU UN TAUTOMERE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/21/1622 20220215 |
| 2797416 | 2022C/537 | Belgium | ⤷ Sign Up | PRODUCT NAME: VOXELOTOR OU UN TAUTOMERE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/21/1622 20220215 |
| 2797416 | CA 2022 00032 | Denmark | ⤷ Sign Up | PRODUCT NAME: VOXELOTOR ELLER EN TAUTOMER ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1622 20220215 |
| 2797416 | CR 2022 00032 | Denmark | ⤷ Sign Up | PRODUCT NAME: VOXELOTOR ELLER EN TAUTOMER ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1622 20220215 |
| 2797416 | PA2022517 | Lithuania | ⤷ Sign Up | PRODUCT NAME: VOKSELOTORAS ARBA TAUTOMERAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ; REGISTRATION NO/DATE: EU/1/21/1622 20220214 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
